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ABSTRACT: 
Annual review exercise testing is recommended by the Cystic Fibrosis (CF) Trust. Testing to 
date has focused on evaluating aerobic fitness, a key prognostic indicator. Tests available 
range from simple field tests, to comprehensive evaluations of aerobic exercise (dys)function 
– cardiopulmonary exercise testing (CPET). 
 
‘Field tests’, although easy to perform are limited in the information they provide. Whereas 
CPET, the ‘gold standard’ measure of aerobic fitness, is recommended as the first choice 
exercise test by the European CF Society Exercise Working Group. CPET offers a precise 
cardiovascular, respiratory and metabolic evaluation of exercise capacity, including 
assessment of mechanism(s) of exercise limitation. 
(100 words) 
 
  
LIST OF ABBREVIATIONS: 
 
CF = Cystic Fibrosis 
CPET = Cardiopulmonary Exercise Test 
FEV1 = Forced expiratory volume in 1 second 
HR = Heart Rate 
SpO2 = Oxygen saturations measured by pulse oximetry V̇O2 = Oxygen Uptake  V̇CO2 = Carbon Dioxide elimination V̇E = Minute ventilation 
VD = Lung dead space 
MVV = Maximal voluntary ventilation 
AT = Anaerobic threshold V̇O2/HR = Oxygen extraction per heart beat – the ‘Oxygen Pulse’ 
  
INTRODUCTION:  
Exercise is an important therapeutic modality for individuals with cystic fibrosis (CF), with 
higher physical activity levels being associated with greater aerobic fitness,1  pulmonary 
function [forced expiratory volume in 1 second (FEV1)],1 glycaemic control,2  and bone 
mineral density.3 Furthermore, exercise training programmes in individuals with CF may 
slow the decline in FEV1,4 and improve lung function,5,6 exercise capacity,6 and quality of 
life.7 Exercise is also shown to enhance mucociliary clearance.8 Importantly, exercise capacity 
is of prognostic significance for CF, with several studies demonstrating that better aerobic 
fitness [maximal oxygen uptake (V̇O2max)] is associated with greater 7-12 year survival.9-11 
 
Exercise physiology – The Basics 
In order to understand data generated from clinical exercise testing, a basic understanding of 
exercise physiology is required. Inadequate training in supervision and interpretation are cited 
as reasons why <10% of UK CF centres perform `gold standard` cardiopulmonary exercise 
testing (CPET).12  
 
Energy generation is facilitated by the metabolism of carbohydrate and/or lipid substrates by 
aerobic (in presence of O2) or anaerobic (in absence of O2) processes in order to generate 
adenosine triphosphate - the energy source which allows muscles to contract. Such reactions 
produce differing amounts of carbon dioxide (CO2) that requires exhalation.   
 
During incremental exercise, V̇O2 increases linearly with workload until peak V̇O2 is attained. 
In some but not all cases, a plateau will be reached where despite further increases in 
workload, V̇O2 can increase no further - termed V̇O2 max. All individuals have a ceiling for 
how much exercise can be performed. Physiologically, we are halted by one of the following 
three mechanisms - ventilatory ability to supply O2, circulatory ability to deliver O2 to and 
remove CO2 from exercising muscles, or muscular extraction and utilisation of O2 for energy 
conversion. Motivation may also contribute (See Figure 1 for overview). 
 
 
Typical exercise response:  
During exercise, breathing patterns adapt to meet energy needs with initial increases in tidal 
volume (VT) and, later, changes in respiratory rate occurring to match demands for V̇O2 and 
CO2 elimination (V̇CO2). Minute ventilation (V̇E) may increase as much as 25-fold with 
exercise, and healthy individuals reach their V̇O2peak at a V̇E max that is short of their maximal 
voluntary ventilation (MVV), with significant ventilatory reserve evident at peak exercise.  
 
Cardiac output is also increased with exercise since both heart rate (HR) and stroke volume 
(SV) increase. Most healthy children have cardiac limitation at maximal exercise, reaching 
HRpeak during CPET. At the muscular level, fatigability and metabolism may also contribute 
to exercise limitation. Deconditioning causes reductions in muscular capillary numbers 
(impaired O2 transfer in exercising muscle), mitochondrial density (impaired O2 utilisation in 
muscle) and oxidative enzyme concentrations (impaired energy transformation in muscle). 
Thus, a deconditioned individual has less capacity for, and a shorter duration of, oxidative 
energy metabolism, with an earlier switch to anaerobic metabolism [anaerobic threshold 
(AT)]. This in turn results in accumulation of fatigue-related metabolites and consequently 
reduces exercise tolerance. 
 
Exercise physiology – What might be different in CF? 
Individuals with CF may have exercise capacity that is similar or greater than many healthy 
individuals, despite some having significantly lower ventilatory reserve at maximal exercise. 
High exercise capacity is especially seen in young children and adolescents with CF who are 
physically active with good lung function. Ventilatory limitation is often not a primary 
limiting factor during exercise in these children, where similar V̇O2peak levels to their healthy 
peers may be recorded. However, some individuals with CF do experience significant 
impairment to exercise capacity due to factors including ventilatory limitation, cardiac and/or 
muscular factors, or commonly physical deconditioning which is at least partially remediable 
with a training programme.  
 
As lung disease severity progresses, ventilatory limitation during exercise is common, with V̇Emax often reached at much lower workloads and V̇O2. Individuals with CF may present with 
increased lung dead space (V̇D) that worsens with lung disease severity, and which can be 
increased during exercise, with higher V̇E needed to achieve similar V̇O2. Additionally, airway 
obstruction due to mucus within the airways (+/- airway hyper-reactivity) may occur in CF, 
requiring greater inspiratory airflows to be generated with greater respiratory muscle effort 
needed to achieve similar ventilation. In contrast to healthy individuals who have significant 
ventilatory reserve at maximal exercise, a person with CF may have an exercise V̇E max that 
reaches or even exceeds predicted MVV.13 In short, those with more severe CF may have higher 
metabolic demands during exercise due to increased work of breathing, as well as a higher V̇Emax, due to increasing physiological V̇D. Such factors, coupled with inability to increase VE 
due to lung disease contribute to ventilatory limitation being the principal factor determining 
exercise capacity in these individuals.  
Cardiac disease and age each affect HR and SV and may limit exercise. Oxygen delivery can 
be investigated during CPET and cardiac (dys)function identified. O2 pulse (V̇O2/HR) measures 
O2 extraction per heart beat and estimates SV. This is important in CF, since some individuals 
are exercise-limited by an inability to sufficiently increase SV.  
 
Muscle-related factors may also play a role in people with CF. Importantly, non-
pathophysiological physical deconditioning may be present. Given the prognostic importance 
of exercise capacity, this may be seen as an important early warning sign for intervention. 
 
It is important to note that much of the value of CPET is that it demonstrates the integration 
of the cardiovascular, pulmonary and muscular systems during exercise. Indeed, many CPET 
tests in CF youth serve to illustrate the capacity for compensation e.g. attaining functionally 
‘normal’ exercise capacity despite having to physiologically compensate for ventilatory or 
other dysfunction. 
 
  
Exercise testing in CF  
 
Why test? 
Exercise is a key component of CF management with annual review exercise testing is 
recommended by the CF Trust.14 Exercise testing allows a functional measure of exercise 
performance. Exercise evaluations facilitates assessment of  interval changes in clinical 
status, and are of prognostic significance,9-11 such that tests identifying poor exercise capacity 
for the degree of lung function deficit warrant prompt attention and act as an early warning of 
impending decline. Exercise testing is also utilised for transplant stratification.15 
 
Undertaking an exercise test may itself have an empowering effect on the individual testee, 
with the demonstration that exercise can often be performed to a high-intensity freeing a 
participant from personal uncertainty and/ or parental fears in future activities. Exercise test 
results can also facilitate exercise programmes tailored to the needs of each individual – e.g. 
improving fitness, or maintenance in those with significant ventilatory limitation but good 
fitness levels.  
 
Furthermore, exercise testing has importance as an outcome measure in clinical trials, with V̇O2peak a secondary outcome of the UK gene therapy study,16 and primary outcome of a 
recently completed phase IV study of Orkambi® (VX15:809-112, Vertex Pharmaceuticals). 
 
 
Which test? 
Available tests of aerobic fitness range from `field` tests to comprehensive analyses of 
aerobic exercise (dys)function, e.g. CPET. Whilst anaerobic (e.g.Wingate) tests and 
evaluations of muscular fatigue/fitness are available, this review focuses on aerobic exercise 
testing. 
 
Field Tests 
Several tests have historically been used to measure aerobic fitness in clinical practice in CF, 
due to their relative ease and low cost. However, these are volitional and often submaximal 
tests, lacking precise outcome measures. Examples include the 6-minute walk test 17 (constant 
workload, non-externally paced, and submaximal for all but the sickest), the 3-minute step 
test 18 (constant workload, submaximal) and shuttle tests.19 Although incremental and 
maximal for many, shuttle tests remain volitional, with no clear ascertainment of maximal 
effort and little insight into the mechanism(s) of exercise limitation. The commonly-used 15-
level version of the 10m shuttle test is submaximal for around 30% of healthy individuals, as 
well as many older children and adults with CF.20 Furthermore, HRpeak and Borg 
breathlessness scores achieved during shuttle testing in CF are lower than that those for 
CPET in the same individuals, suggesting greater effort expenditure on CPET.21 Collectively, 
these limitations highlight the need for more precise and detailed exercise testing where 
possible. 
 
CPET 
The authors firmly support CPET as the test of choice for both children and adults with CF, 
in line with the European CF Society (ECFS) exercise working group recommendations.22 
Measurement of V̇O2peak by CPET is regarded as the gold standard method to evaluate aerobic 
fitness. Cycle ergometry with breath-by-breath analysis of gas exchange and ventilation 
offers a comprehensive exercise assessment of ventilatory, circulatory, and metabolic 
parameters during various exercise intensities. Workload is progressively increased 
incrementally during CPET using a `step` or ramp protocol, such that exercise responses up 
to and including maximal exercise can be measured within 8-12 minutes. Key measures of 
interest include V̇O2peak, V̇O2 at the ventilatory AT, and V̇Emax in addition to peak power 
output, change in O2 saturation (SpO2), time to exhaustion, and effort and breathlessness 
ratings. CPET allows evaluation of the mechanism(s) of exercise limitation.  
 
The recommended protocol for individuals with CF aged >10 years22 is cycle ergometry using 
the Godfrey incremental exercise protocol23 with monitoring of SpO2, pulmonary gas 
exchange, ventilation, and HR. The stepwise increments (10 to 25W/min) used are based on 
stature and target an 8-12 minute test duration. Continuous ramp protocols are advocated by 
some, since the increments increase continuously similar to physiological responses.24 Cycle 
ergometry with pulse oximetry only (but no gas exchange measures), or treadmill exercise tests 
are recommended as second best options.22 The modified Bruce protocol is recommended for 
treadmill testing. 
 
The main limitations to undertaking CPET are equipment costs and operator expertise, 
however in our opinion the value of the information provided justifies the need to invest in 
equipment and skills training. CPET tests generate a large dataset usually displayed in a 
series of graphs, known as the 9-panel plot (see Figures 2 and 3), which are used to measure 
or estimate key exercise parameters including V̇O2, V̇Emax, and the AT. 
 
After checking data quality, one should first review V̇O2peak and maximum workload to assess 
whether they are normal relative to appropriate (age, sex, and ethnicity) normative reference 
data. In addition, it is important to consider whether maximum effort has been reached with 
respect to HRpeak, respiratory exchange ratio at peak exercise and whether or not V̇O2 has 
plateaued at the end of exercise. If maximal exercise endpoints are unclear, supramaximal 
exercise testing to verify V̇O2 peak can be considered.24An abnormally low exercise capacity is 
defined as V̇O2peak <80% predicted. The next challenge is to identify whether reduced V̇O2peak 
may be due to cardiovascular and/or peripheral muscle disease, or as is more likely in more 
severe CF, the result of deconditioning and/or ventilatory limitation (Figure 1).  
 
The normal mechanism for exercise termination in a healthy individual is cardiac limitation, 
with HRpeak being attained (no cardiac reserve) and V̇E falling short of estimated MVV i.e. gas 
in the tank at the end of exercise – exercise V̇E < 85% MVV.22 The physiology in children 
differs from adults, and expected HRpeak falls with age, whilst children with CF often achieve 
a HRmax >200 beats/min during CPET. 
 
 
AT onset provides a submaximal indicator of an individual’s aerobic fitness. Deconditioning 
results in an early onset AT, indicative of reduced efficiency to transfer and utilise O2 at the 
muscular level. An AT occurring < 50% predicted V̇O2max (in the absence of cardiac disease or 
muscle abnormalities) is likely to be associated with deconditioning, and can be improved with 
training.  
 
Who to test? 
It is recommended that CPET has a role in providing guidance on prognosis and allowing 
individualised exercise counselling in CF from 10 years of age.22 This age is recommended as 
a guide for those undertaking CPET using a cycle ergometer, since the participants are 
required to maintain cadence when pedalling, which some children find difficult, in addition 
to reaching the pedals (minimum height ~ 128 cm in our exercise laboratories), though 
technically acceptable tests can be achieved in younger children. It may be that ergometer 
tests in younger children can be attempted to familiarise them with procedures as well as 
providing motivation and guidance for exercise participation; and treadmill tests may also be 
performed in younger children (with or without a safety harness). A recently published 
review for this journal offers advice on how to perform, interpret and use CPET to guide 
exercise counselling in children with CF.25 
 
When to test? 
Interval CPET testing is recommended for children and adults with CF.22 In our centres we 
recommend that annual CPET is undertaken as part of annual review. In addition, exercise 
testing plays a vital role in pre-transplant assessment, with both 6MWT and CPET14 being 
validated for this purpose. Exercise testing before and after significant change or intervention 
is recommended, e.g. before/after the institution of Ivacaftor26 or Orkambi®.   
CASE EXAMPLE: 
Patient A (FEV1 95%pred), male (p.Phe508del/p.Ala457Pro, c.1369G>C) and aged 13 years 
attended for CPET at annual review. He attained V̇O2peak of 38.7mL/kg/min (84% predicted), 
and HRpeak 184 beats/min. He had significant breathing reserve at peak exercise (V̇Emax 
77L/min versus calculated MVV 108L/min), and had V̇O2 at AT of 40%pred V̇O2max. CPET 
suggested suboptimal exercise capacity, with deconditioning suggested by early onset of AT. 
Selected data from panels 3,4, and 5 of his 9-panel plot are displayed (Figure 2). 
 
An action plan was made by physiotherapy colleagues who devised an individualised 
exercise programme. Improvements in both exercise capacity and physical conditioning were 
evident upon retesting 5 months later (Figure 3). V̇O2peak was 43.2mL/kg/min (96% 
predicted), and V̇O2 at AT had improved to 48%pred V̇O2max. An identical HRpeak and similar 
breathing reserve were recorded.  
 
CONCLUSIONS 
Traditional testing of lung health using spirometry tells us how much and how fast air exits 
the lungs. Measurement of efficiency and performance of these lungs in combination with 
cardiovascular, pulmonary and musculoskeletal systems during exercise (CPET) provides 
precise information that is of prognostic importance, as well as allowing us to further 
understand individual pathophysiology of exercise limitation and individually tailor exercise 
programmes for young people with CF. 
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Figure 1 
Schematic overview of how to determine exercise function and/or cause of any dysfunction 
in individuals with CF 
 
 
 
 
 
Figure reproduced with permission from: 
Urquhart and Vendrusculo, Paediatr Respir Rev 2017;24:72-78.21 
  
Figure 2 
Case example illustrating an exercise-limited and deconditioned CF patient (Selected data (Panels 3,4,5 shown) from CPET are displayed)  
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Figure 3 
Improvements in exercise capacity and AT in same patient following individualised exercise programme  
(Selected data (Panels 3,4,5 shown) from CPET are displayed) 
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